Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04577729
Other study ID # CA-209-7HP
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date May 21, 2021
Est. completion date June 7, 2023

Study information

Verified date July 2023
Source Medical University of Graz
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Aim of the study is to investigate the effect of Fecal Microbiota Transplantation (FMT) and Checkpoint Inhibitor (CI) re-challenge in prior CI refractory patients on Progression free survival (PFS) and tumor using donor stool of former malignant melanoma patients, who have been in remission due to CI treatment for at least 1 year.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date June 7, 2023
Est. primary completion date June 7, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients with histologically confirmed malignant melanoma - Age > 18 years - Written consent of the participant after being informed - Contraception as described in protocol appendix section VI 2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): PS 0 to 1. 3. Previously treated, unresectable stage III or stage IV melanoma as per the American Joint Committee on Cancer 2017 Guidelines (8th Edition) regardless of BRAF mutation status. 4. Patients must have experienced disease progression or recurrence during treatment with an anti-PD-1 monoclonal antibody, not having OR not willing to accept other approved systemic treatment options (like: BRAF and MEK inhibitors in BRAF V600 mutated melanoma). 5. Patients with CNS (central nervous system) metastases: - Patients are eligible if CNS metastases are treated and subjects are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks Prior to enrolment. In addition, patients must be either off corticosteroids or on a stable or decreasing dose <10 mg daily prednisone (or equivalent) OR - Patients are eligible if they have previously untreated CNS metastases and are neurologically asymptomatic. In addition, patients must be either off corticosteroids or on a stable or decreasing dose of <10 mg daily prednisone (or equivalent) OR - Patients with additional leptomeningeal metastases are eligible if they are treated and neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrolment and have an estimated life expectancy of at least 3 months. In addition, subjects must be either off corticosteroids or on a stable or decreasing dose of <10 mg daily prednisone (or equivalent) 6. Patients must have evaluable disease by CT (computer tomography) or MRI (magnet resonance imaging) per RECIST 1.1 criteria (Appendix 3) (radiographic tumor assessment performed before as well as after 10 weeks of first dose of study drug) or clinically apparent disease that the investigator can follow for response. Exclusion Criteria: 1. Active brain metastases or leptomeningeal metastases. Participants with brain metastases are eligible if these have been treated and there is no MRI evidence of progression for at least 2 weeks after treatment is complete and within 28 days prior to first dose of study treatment administration. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study treatment administration. Stable dose of anticonvulsants is allowed. Treatment for CNS metastases may include stereotactic radiosurgery (e.g. GammaKnife, CyberKnife, or equivalent) or neurosurgical resection. Patients who received whole brain radiation therapy are not eligible. 2. Prior treatment with chemotherapy, interferon (adjuvant setting), IL-2 (Interleukin-2), BRAF/MEK Inhibitors (v-Raf murine sarcoma viral oncogene homolog B/Mitogen-Activated Protein Kinase) for subjects with known BRAF V600 mutations, MEK inhibitors for NRAS (N-Rat sarcoma) mutations, and cKIT (Tyrosinkinase) Inhibitor subjects with known cKIT mutations is NOT allowed. 3. Uveal melanoma is excluded. 4. Coexisting severe chronic diseases other than melanoma (other neoplasias, autoimmune diseases,…). 5. Secondary gastrointestinal motility disorders. 6. Pregnancy and breast feeding. 7. Large abdominal surgery in medical history. 8. Intake of any medication introduced by another clinical study. 9. Any conditions (e.g. allergies), that do not allow the administration or intake of any of the substances used in this study (Nivolumab, Vancomycin, colonic lavage fluid).

Study Design


Intervention

Procedure:
Allogenic Fecal Microbiota Transplantation
Patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
Autologous Fecal Microbiota Transplantation
Patients receiving their own stool in terms of sham FMT.

Locations

Country Name City State
Austria Medical University of Graz Graz

Sponsors (2)

Lead Sponsor Collaborator
Medical University of Graz Bristol-Myers Squibb

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival (PFS) Patients undergoing CI therapy after FMT will be evaluated by Immune-RECIST (iRECIST) criteria after contrast-enhanced CT-scan in order to determine disease progression. 3 months after checkpoint inhibitor (CI) therapy following fecal microbiota transplantation (FMT).
Secondary Tumor response (CR, PR, SD) Complete response (CR), partial response (PR) and stable disease (SD) of target or non-target lesions are considered tumor response in this trial according to iRECIST criteria after three months. 3 months after checkpoint inhibitor (CI) therapy following FMT.
Secondary Detection of specific donor signaling in intestinal microbiota leading to response to CI therapy. A total of five donors will be included in the study. The allogenic-FMT group will receive donor stool from a single donor per patient for both, the primary FMT and a scheduled booster FMT. Donors will be divided into those, who successfully improved PFS and/or tumor response versus those, who were not able to induce treatment response. Donor stool will be evaluated by 16s-RNA analysis. 3 months after checkpoint inhibitor (CI) therapy following FMT.
Secondary Detection of specific patients' microbiota pre and post FMT leading to response. Patients will be divided into responders and nonresponders and microbiota will be analyzed via 16s-RNA analysis before and after FMT. We will look into specific donor-signaling in patients stool samples after FMT, as well as trying to identify groups of intestinal microbiota associated with higher response rates to CI re-challenge. 3 months after checkpoint inhibitor (CI) therapy following FMT.
Secondary Frequency of Adverse Events categorized according to the CTCAE grading system Version 4.0 To evaluate safety and toxicity of CI therapy after FMT vs. control group. Drug toxicity will be monitored, categorized according to the CTCAE grading system Version 4.0 and managed according to recent recommendations by the SITC Toxicity Management Working Group. 3 months after checkpoint inhibitor (CI) therapy following FMT.
Secondary Serum Neutrophil-to-Lymphocyte Ratio (NLR) pre- and post-FMT as an indicator for response. In our study we will look at potential alterations in NLR after FMT and whether this can indicate response to CI treatment after FMT. 3 months after checkpoint inhibitor (CI) therapy following FMT.
Secondary Detection of differences between primary and secondary non-responders to CI therapy and their specific outcome after FMT by performing a subgroup analysis. To date and according to present data we do not know, whether primary or secondary non-responders may have a better potential to respond to FMT in order to reach PFS under CI rechallenge. Hence, a subgroup analysis will be performed, in order to identify patient groups best suited for such treatment in the future. 3 months after checkpoint inhibitor (CI) therapy following FMT.
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04436874 - Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease N/A
Recruiting NCT03325855 - Fecal Microbiota Transplant National Registry
Completed NCT06162702 - Clinical Study of Fecal Microbiota Transplantation in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) N/A
Active, not recruiting NCT05607745 - Dietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB Study N/A
Completed NCT05121285 - Distribution of FMT After Delivery by · Lower GI Endoscopy vs Enema With and Without Positioning of the Patient N/A
Active, not recruiting NCT05917379 - The Safety and Efficacy of FMT in Patients With CID Phase 1/Phase 2
Recruiting NCT02318147 - Fecal Microbiota Transplantation for Pancreatitis With Infectious Complications(FMTPIC) Phase 1
Completed NCT02318134 - Fecal Microbiota Transplantation for Pancreatitis Phase 2
Completed NCT05035784 - RCE With FMT in the Treatment of Childhood Constipation N/A
Active, not recruiting NCT04173208 - Main Trial of the Cesarean Section and Intestinal Flora of the Newborn Study N/A
Not yet recruiting NCT02435160 - The Study of Efficacy and Mechanism in Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT04837313 - Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Parkinson's Disease With Constipation N/A
Recruiting NCT04861649 - Metabonomics of COPD and Transplanting of Faecal Bacteria in the Treatment of Its Malnutrition N/A
Withdrawn NCT04078581 - Profiling Fecal Samples for Selection of Donors of Feces N/A
Recruiting NCT05821010 - Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis Phase 2
Recruiting NCT05273255 - Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy N/A
Not yet recruiting NCT05253222 - Methodology and Clinical Value of RIT in Intestinal Obstructive Diseases Mediated by Colonic TET N/A
Recruiting NCT04285424 - FMT for Steroid Resistant Gut Acute GVHD Early Phase 1
Withdrawn NCT03527056 - Pilot Study Using Oral Capsule FMT to Decolonize GI CRE Early Phase 1
Recruiting NCT03018613 - Fecal Microbiota Transplantation for Chronic Functional Constipation Phase 1/Phase 2